In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Relay Therapeutics Inc (NASDAQ: RLAY) closed the day trading at $7.79 up 2.64% from the previous closing price of $7.59. In other words, the price has increased by $2.64 from its previous closing price. On the day, 1.31 million shares were traded. RLAY stock price reached its highest trading level at $7.89 during the session, while it also had its lowest trading level at $7.55.
Ratios:
For a better understanding of RLAY, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.14 and its Current Ratio is at 19.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4. Jefferies Upgraded its Hold to Buy on September 10, 2024, whereas the target price for the stock was revised from $10.60 to $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 03 ’25 when Patel Sanjiv sold 62,073 shares for $7.00 per share. The transaction valued at 434,511 led to the insider holds 703,215 shares of the business.
Rahmer Peter sold 21,394 shares of RLAY for $160,455 on Oct 29 ’25. The insider now owns 337,469 shares after completing the transaction at $7.50 per share. On Oct 28 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 19,135 shares for $7.29 each. As a result, the insider received 139,494 and left with 358,863 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1350181376 and an Enterprise Value of 787079360. For the stock, the TTM Price-to-Sale (P/S) ratio is 161.51 while its Price-to-Book (P/B) ratio in mrq is 2.21. Its current Enterprise Value per Revenue stands at 94.205 whereas that against EBITDA is -2.456.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.57, which has changed by 0.6539278 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $8.36, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 13.73%, while the 200-Day Moving Average is calculated to be 83.12%.
Shares Statistics:
Over the past 3-months, RLAY traded about 1.99M shares per day on average, while over the past 10 days, RLAY traded about 1697980 shares per day. A total of 172.63M shares are outstanding, with a floating share count of 130.18M. Insiders hold about 24.89% of the company’s shares, while institutions hold 74.70% stake in the company. Shares short for RLAY as of 1764288000 were 23160072 with a Short Ratio of 11.62, compared to 1761868800 on 17870256. Therefore, it implies a Short% of Shares Outstanding of 23160072 and a Short% of Float of 16.189999999999998.
Earnings Estimates
The dynamic stock of Relay Therapeutics Inc (RLAY) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.38 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.5 and -$2.08 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.58, with 7.0 analysts recommending between -$1.43 and -$1.78.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8.36M, resulting in an average revenue estimate of $12.91M. In the same quarter a year ago, actual revenue was $10.01M
